Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Walt Disney Co (DIS) vs 10X Genomics Inc (TXG) Price & Performance

Walt Disney CoTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Walt Disney Co vs 10X Genomics Inc — how do they compare? Walt Disney Co trades at $95.8 (market cap $166.48B), while 10X Genomics Inc trades at $45.9 (market cap $5.81B). The key difference: Walt Disney Co is far larger — about 28.7× 10X Genomics Inc's market cap, and Walt Disney Co pays a 1.56% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

DISTXG
Market Cap
$166.48B$5.81B
Volume
7,546,013
Sector
MediaHealth
52-Week High
$122.94$45.80
52-Week Low
$92.40$11.34
Enterprise Value
$208.16B$5.36B
Dividend Yield
1.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Walt Disney Co

Disney (DIS) trades at $96.01, up 0.4% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats. Revenue grew to $94.43B in 2025 with net income surging to $12.40B. The stock shows a P/E of 15.34 and P/S of 1.77, trading below the consensus price target of $125.60. Recent news highlights advertising opportunities from major events like the Super Bowl, though box office performance for new Star Wars film raises concerns.

Outlook remains positive with analyst consensus at Buy (61.9%) and a 31% upside to target, driven by earnings momentum and theme park investments. Risks include regulatory disputes with the FCC, streaming competition, and film profitability. Cash flow trends show operational strength but negative net flows from high investing activity.

10X Genomics Inc

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Walt Disney Co

The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.

Read more on DIS

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG